GAUDIUMIVF

Gaudium IVF and Women Health Limited

Gaudium IVF and Women Health Limited (GAUDIUMIVF) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Healthcare Services›Healthcare Service Provider

gaudiumivfcentre.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹101.46
Market cap
738 Cr
Stock P/E
30.2 · FY26
P/B
4.85
ROE (FY26)
16.1%
ROCE (FY26)
20.3%
Operating margin (FY26)
33.7%
Debt / equity (FY26)
0.15
OCF / EBITDA (FY26)
19.2%
OCF / EBITDA (3Y)
22.7%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Gaudium IVF runs fertility clinics that offer IVF (in vitro fertilisation) treatment to couples in India, through a network of larger hubs and smaller spokes in several states.

Company snapshot

10thBy market cap

Ranked among 10 companies in Healthcare Service Provider.

What we see

Positives
  • ✓Net margin of 23.4% — the business keeps a healthy share of every rupee it earns.
Concerns
  • ✗Only 23% of operating profit came in as cash over the last three years — much of it is tied up in unpaid bills or stock.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricDec 2025Mar 2026Jun 2026
Sales25 Cr30 Cr19 Cr
Operating expenses (approx.)18 Cr18 Cr17 Cr
EBITDA7 Cr12 Cr2 Cr
OPM %26.7%40.1%12.5%
Other income0.10 Cr0.18 Cr1 Cr
Interest1 Cr1 Cr0.38 Cr
Depreciation0.49 Cr0.64 Cr0.72 Cr
Profit before tax5 Cr10 Cr2 Cr
Tax %26.9%19.8%27.5%
Net profit4 Cr8 Cr2 Cr
EPS (₹)₹0.59₹1.34₹0.25

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2023Mar 2024Mar 2025Mar 2026TTM
Sales44 Cr48 Cr71 Cr104 CrSign in free for the trailing twelve months
Operating expenses (approx.)24 Cr29 Cr42 Cr67 CrSign in free for the trailing twelve months
EBITDA20 Cr19 Cr29 Cr38 CrSign in free for the trailing twelve months
OPM %45.4%40.2%40.5%36.1%Sign in free for the trailing twelve months
Other income0.02 Cr0.26 Cr0.23 Cr0.53 CrSign in free for the trailing twelve months
Interest0.34 Cr0.75 Cr1 Cr3 CrSign in free for the trailing twelve months
Depreciation1 Cr2 Cr2 Cr3 CrSign in free for the trailing twelve months
Profit before tax18 Cr17 Cr25 Cr32 CrSign in free for the trailing twelve months
Tax %26.1%38.0%24.8%24.0%Sign in free for the trailing twelve months
Net profit14 Cr10 Cr19 Cr24 CrSign in free for the trailing twelve months
EPS (₹)₹2.20₹1.68₹3.12₹3.92Sign in free for the trailing twelve months
Dividend payout %———0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2023Mar 2024Mar 2025Mar 2026
Equity capital0.99 Cr0.99 Cr31 Cr36 Cr
Reserves22 Cr26 Cr16 Cr116 Cr
Borrowings10 Cr16 Cr19 Cr23 Cr
Other liabilities4 Cr8 Cr23 Cr18 Cr
Total liabilities37 Cr51 Cr89 Cr193 Cr
Fixed assets (net)4 Cr6 Cr6 Cr7 Cr
CWIP0.13 Cr0.13 Cr7 Cr0 Cr
Investments0.0010 Cr—5 Cr5 Cr
Inventories1 Cr2 Cr7 Cr4 Cr
Trade receivables0.91 Cr14 Cr33 Cr53 Cr
Cash & bank15 Cr12 Cr7 Cr9 Cr
Other assets15 Cr18 Cr22 Cr115 Cr
Total assets37 Cr51 Cr89 Cr193 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity24 Cr3 Cr9 Cr7 Cr
Cash from investing-16 Cr-5 Cr-15 Cr-88 Cr
Cash from financing5 Cr-1 Cr2 Cr82 Cr
Net cash flow13 Cr-3 Cr-5 Cr2 Cr
Free cash flow (OCF − Capex)9 Cr0.65 Cr-0.16 Cr0.53 Cr

Ratios

MetricMar 2023Mar 2024Mar 2025Mar 2026
ROCE %57.4%40.7%41.1%20.3%
ROE %59.5%38.2%41.3%16.1%
Debtor days7104169186
Inventory days9214813012
Days payable635425143
Cash conversion cycle3619848156
OCF / EBITDA %118.9%17.9%30.5%19.2%
OCF / EBITDA % (3 years)——53.0%22.7%
Debt / equity0.430.580.410.15
Current ratio1.921.501.421.90
Net debt / EBITDA-0.260.200.410.38